- Country: USA
- Summary: 6 months of Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source)
- UST Ref No: 117761323
- Deadline: 21 Apr 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: NOI-CC-25-000022
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
Acquisition Description:
This is a Notice of Intent, not a request for proposal. The National Institute of Health, Clinical Center (NIH-CC) intends to negotiate on an other than full and open competition basis with Cardinal Health. This requirement will be sole sourced to Cardinal Health under FAR 13.501(a) or 8.405-6 (b) - sole source requirements.
The National Institutes of Health (NIH) Clinical Center (CC) (NIH-CC or “Program”) is a clinical research hospital providing all medical services for patients participating in human research protocols of the NIH. The CC Pharmacy department provides a range of pharmaceutical care services to inpatients and outpatients enrolled in clinical trials. The CC Pharmacy department is responsible for acquiring the supply of medications required for patient care. The NIH-CC has a pharmacy center that requires Sirturo (Bedaquiline) drug tablets for patient care.. Sirturo is supplied in the following forms: 100 mg tablets in 188 count bottles and 20 mg tablets in 60 count bottles. Various different quantities are needed every year. Based on Program-s purchase history in the past, and factoring in the anticipated patient enrollment, Program expects to need approximately 12 - 36 bottles of each type of Sirturo® bottles per year.
This current requirement is for approximately half a year-s worth of Sirturo drugs.
Justification:
Only this Sirturo medication can be accepted as there are no substitutes for this medication. The manufacturer (Janssen Therapeutics) has designated Cardinal Health (DBA Metro Medical Supply) as the sole distributor of Sirturo drugs in the U.S.
Previous acquisitions and research indicated that this requirement should be a sole source requirement. For the previous acquisitions, a Notice of Intent was posted on Beta.Sam.Gov May 15, 2020 and closing May 31, 2020. Cardinal Health/Metro Medical responded with a Sole Source notice. In order to confirm this is still applicable, th... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGIN6 months of Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source) - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for 6 months of Sirturo (Bedaquiline) tablets for the NIH (Notice of Intent to sole source). This tender is published on USARFP under UST Ref No: 117761323 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-04-21.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
